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We previously reported a genomewide scan to identify autism-susceptibility loci in 110 multiplex families, showing
suggestive evidence (P ! .01) for linkage to autism-spectrum disorders (ASD) on chromosomes 5, 8, 16, 19, and
X and showing nominal evidence (P ! .05) on several additional chromosomes (2, 3, 4, 10, 11, 12, 15, 18, and
20). In this follow-up analysis we have increased the sample size threefold, while holding the study design constant,
so that we now report 345 multiplex families, each with at least two siblings affected with autism or ASD phenotype.
Along with 235 new multiplex families, 73 new microsatellite markers were also added in 10 regions, thereby
increasing the marker density at these strategic locations from 10 cM to ∼2 cM and bringing the total number of
markers to 408 over the entire genome. Multipoint maximum LOD scores (MLS) obtained from affected–sib-pair
analysis of all 345 families yielded suggestive evidence for linkage on chromosomes 17, 5, 11, 4, and 8 (listed in
order by MLS) (P ! .01). The most signiﬁcant ﬁndings were an MLS of 2.83 (P p .00029) on chromosome 17q,
near the serotonin transporter (5-hydroxytryptamine transporter [5-HTT]), and an MLS of 2.54 (Pp .00059) on
5p. The present follow-up genome scan, which used a consistent research design across studies and examined the
largest ASD sample collection reported to date, gave either equivalent or marginally increased evidence for linkage
at several chromosomal regions implicated in our previous scan but eliminated evidence for linkage at other regions.
Introduction
Autism [MIM 209850] is a neuropsychiatric develop-
mental disorder with a prevalence of 4–10 per 10,000
individuals (Smalley et al. 1988; Gillberg and Wing
1999; Fombonne et al. 2002) and a three- to fourfold
higher incidence in boys than in girls (Folstein and Ro-
sen-Sheidley 2001). Essential diagnostic features of au-
tism include severe impairment in development of social
interactions, a marked and sustained impairment of both
verbal and nonverbal communication, and restricted, re-
petitive, or stereotyped behaviors and interests (Ameri-
can Psychiatric Association 2000), occurring within the
ﬁrst 3 years of life. Autism describes the most severe
manifestation of a broad spectrum of disorders that in-
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clude Asperger syndrome (AS [MIM 209850]) and are
collectively categorized as “pervasive developmental dis-
orders” (PDDs [MIM 209850]). It is recognized that
autism and these autism spectrum disorders (ASD),
which have a much higher prevalence of 10–60 individ-
uals per 10,000 (Chakrabarti and Fombonne 2001;
Charman 2002; Yeargin-Allsopp et al. 2003), share es-
sential clinical and behavioral features although they dif-
fer in severity and age at onset.
Evidence from twin and family studies clearly estab-
lishes the importance of genetic factors in the devel-
opment of autism and ASD (Folstein and Rutter 1977;
Bailey et al. 1995). MZ twins show 40%–60% and
70%–90% concordance for autism and ASD, respec-
tively, compared with rates of 0%–25% concordance,
depending on diagnosis, among DZ twins (Folstein and
Rutter 1977; Steffenburg et al. 1989; Bailey et al. 1995;
Lauritsen et al. 2001). Although an accurate estimation
of the population prevalence is complicated by an ap-
parent increase in autism over recent decades (Gillberg
and Wing 1999), it is clear that the estimated sibling
recurrence risk of 2%–6% is signiﬁcantly greater than
risk of .04%–.1% in the general population (Smalley
et al. 1988; Smalley 1997; Szatmari et al. 1998; Gillberg
and Wing 1999). The estimated sibling risk for autism
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is therefore 50–100 times greater than the population
risk (Lamb et al. 2000). The studies cited above indicate
that autism and ASD are highly heritable, with some
studies of ASD reporting heritability 190% (Bailey et
al. 1995). However, these studies also make it clear that
ASDs are complex genetic disorders that most likely
result from the combinatorial effects of multiple genetic
and environmental factors.
Nine independent genomewide scans with DNA
markers have been performed to try to detect genetic
variation related to autism or ASD (International Mo-
lecular Genetic Study of Autism Consortium [IMGSAC]
1998, 2001b; Barrett et al. 1999; Risch et al. 1999;
Philippe et al. 1999; Buxbaum et al. 2001; Liu et al.
2001; Auranen et al. 2002; Shao et al. 2002). Although
nominal suggestive evidence for linkage between DNA
markers and given ASD phenotypes has been reported
on 17 of the 22 autosomes and at various locations on
the X chromosome, only a few regions appear to be
supported by independent studies (Folstein and Rosen-
Sheidley 2001). The most consistent ﬁnding to date,
which is supported by meta-analysis, has been on chro-
mosome 7q (Badner and Gershon 2002). A study from
the IMGSAC provided initial evidence of genomewide
linkage to 7q, in a study of 99 families, and subsequently
strengthened the ﬁndings with the addition of 83 sib
pairs and high-density markers across the implicated
region (IMGSAC 1998, 2001b, 2001a). Several inde-
pendent studies have produced nominal-to-suggestive
evidence of linkage to ASD phenotypes on 7q as well
(Barrett et al. 1999; Buxbaum et al. 2001; Liu et al.
2001; Alarco´n et al. 2002; Auranen et al. 2002; Shao
et al. 2002).
We previously reported genomewide screens for au-
tism- and ASD-related loci in 110 families and for a
language-development quantitative-trait locus (QTL) in
152 multiplex families, along with a dense-marker
screen covering much of chromosome 7 in a total of
160 multiplex families from the Autism Genetic Re-
source Exchange (AGRE) (Liu et al. 2001; Alarco´n et
al. 2002). Analysis of these initial studies yielded sug-
gestive evidence for linkage on chromosomes 5q, 19p,
and X (Liu et al. 2001), as well as suggestive evidence
of a speech- and language-related locus on 7q (Alarco´n
et al. 2002). In the present study, we have added 235
new multiplex families affected by autism. The ascer-
tainment scheme, diagnostic methods, microsatellite
markers, and genetic analysis were all maintained from
the initial study, although the pedigree and phenotype
information for some of the original families has been
updated since our last analyses. Here, we present the
results of a genomewide scan with 408 microsatellite
markers and 345 multiplex families, each with a min-
imum of two individuals who met criteria for a diag-
nosis of autism or ASD.
Families and Methods
Family Recruitment and Diagnosis
The sample comprises 345 multiplex families with
ASD from the AGRE, a publicly available database con-
sisting of biomaterials and genotype and phenotype data
that was founded by the Cure Autism Now Foundation
and is now supported by theNational Institute ofMental
Health (NIMH) as part of the NIMH genetics initiative.
Families are recruited through a variety of methods (e.g.,
physician referral, Web site contact, and family meetings
and seminars). They are ascertained on the basis that at
least two family members met criteria for a diagnosis
of an ASD (autism, AS, or PDD). Of these families,
110 have been analyzed elsewhere by our group (Liu et
al. 2001; Alarco´n et al. 2002); the present study adds
235 new families. Family recruitment and phenotypic
assessment of the AGRE sample were conducted as de-
scribed elsewhere (Geschwind et al. 2001). Diagnosis is
established by the Autism Diagnostic Interview–Revised
(ADI-R) (Lord et al. 1994). The ADI-R is currently the
gold standard for research diagnosis and is based on the
classiﬁcations of both the International Statistical Clas-
siﬁcation of Diseases and Related Health Problems, 10th
revision (World Health Organization 1992) as well as
the Diagnostic and Statistical Manual of Mental Dis-
orders, 4th edition (American Psychiatric Association
2000). To be scored as affected, individuals must meet
criteria in all three content areas of the ADI-R: (1) qual-
ity of social interaction, communication, and language;
(2) repetitive, restricted, and stereotyped interests and
behavior; and (3) age at onset !3 years (Lord et al. 1994).
Collection of additional clinical and neurodevelopmental
information is ongoing and has been obtained from 160
families; additional information was obtained through a
medical examination and use of the Autism Diagnostic
Observation Scale (Lord et al. 2001). Possible nonidio-
pathic autism cases are ﬂagged in the AGRE data set
(e.g., fragile X syndrome or perinatal insult) and are
excluded from any genotyping and analysis.
In accordance with methods described elsewhere (Liu
et al. 2001), the present study used two diagnostic cat-
egories for genetic linkage analysis: narrow and broad.
The narrow category includes individuals with a diag-
nosis of autism based on the ADI-R (664 individuals of
a total of 1,795), as well as individuals who were cat-
egorized as having a disorder that was “not quite au-
tism” (NQA) (52 individuals of a total of 1,795). The
inclusion of NQA individuals in the narrow category is
consistent with results of the genome scan we reported
elsewhere (Liu et al. 2001). The categorization of NQA
represents individuals who are no more than 1 point
away from meeting criteria for autism in any or all of
the three content domains or individuals who meet cri-
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Table 1
Summary of AGRE Families
PHENOTYPE
DEFINITION








Families Probands Families Probands Families Probands Families Probands
Narrow 285 716 265 530 17 51 3 12
Broad 345 833 307 614 34 102 4 16
NOTE.—Data summarize structure of families in the narrowly and broadly deﬁned phenotype groups (as
described in “Families and Methods” section).
teria in all domains but do not meet age-at-onset criteria.
Thus, they are individuals who would be identiﬁed by
most clinicians as autistic but who narrowly miss meet-
ing the ADI-R criteria. The broad category includes all
individuals in the narrow category, as well as those who
show patterns of impairment along the spectrum of PDDs
(117 individuals designated as “broad spectrum”plus664
as “autism” plus 52 as “NQA”). This broad diagnostic
category encompasses individuals ranging from mildly to
severely impaired and includes such PDDs as PDD–not
otherwise speciﬁed and Asperger syndrome (full diag-
nostic protocol is available on the Autism Genetic Re-
source ExchangeWeb page). Multipoint affected–sib-pair
(ASP) analysis based on only the strictest deﬁnition of
autism was also performed, thereby excluding the 52
NQA individuals as affected siblings, although this anal-
ysis was not used to determine linkage results. Our sam-
ple contains 345 families that have two or more indi-
viduals that meet the diagnostic criteria for the broad
diagnosis. Of those families, 7 have no members with
the narrow diagnosis, 53 have only 1 member with the
narrow diagnosis, and 285 have 2 members with the
narrow diagnosis. Thus, the analyses for the narrow di-
agnosis are based on 285 families, whereas the analyses
for the broad diagnosis utilize all 345 families. The ma-
jority of the families reported here have two affected
siblings (307 of 345 families), although 34 families have
three affected siblings, and 4 families have four affected
siblings (table 1).
A total of 362 families were phenotyped and geno-
typed, including 12 families whose only affected siblings
were MZ twins. These 12 families were purposely in-
cluded as an internal control, to estimate detectable ge-
notyping errors, but were excluded from linkage anal-
ysis. After removal of an additional 5 families in which
genotyping was unsuccessful, we were left with 345 fam-
ilies that included 2 affected siblings, providing a total
of 381 sib pairs that fall into the broad disease classi-
ﬁcation. The narrow disease classiﬁcation, comprising
autism and NQA, consists of 285 families and a total
of 321 sib pairs.
Since our previous report (Liu et al. 2001), AGRE has
updated family relationships and diagnostic informa-
tion, leading to corrections in six pedigrees and 35 phe-
notypes among the original 110 families. Reanalysis of
the 110 families with the new pedigree and phenotype
information reﬂects these changes in relation to the link-
age results reported elsewhere (data indicated as appro-
priate in the “Results” section). In addition, given that
MZ twins are identical at every locus, both twins cannot
be used in genetic analysis, because they will inﬂate link-
age values at every point in the genome. Therefore, as
in our previous study, one of each MZ twin pair was
randomly removed. In those families in which the MZ
twins were the only affected individuals, the entire family
was removed, because it was no longer informative for
ASP analysis. We also previously reported a ﬁne-map
analysis of chromosome 7 that included an additional
50 families (Liu et al. 2001). Among those 50 families,
46 have now been genotyped over the entire genome
and represent a fraction of the 235 new families added
in this study. However, 2 of the 50 families were elim-
inated when purported DZ twins were determined to be
MZ, and 2 other families were removed because they
were found to have only one affected child, on the basis
of the updated phenotypic information.
Genotyping
Laboratory and genotyping procedures have been de-
scribed in detail elsewhere (Liu et al. 2001). Blood was
drawn from affected individuals, as well as from parents
and unaffected siblings (when available). DNA was ex-
tracted from whole blood or immortalized lymphoblast
cell lines after standard proteinase digestion and salting-
out protocols (Medrano et al. 1990). The DNA marker
panel consisted of a set of 408 microsatellite markers,
which includes the entire 335 microsatellite marker
panel used in our previous genomewide scan (Liu et al.
2001) plus an additional 73 microsatellite markers spe-
ciﬁcally selected to augment information from peakMLS
regions determined after an intermediate analysis (110
plus 46 additional families), increasing marker density
to an average of 2 cM in these regions. Thirty of these
73 additional markers span a region of ∼60 cM on chro-
mosome 7q. The majority of all microsatellite markers
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were selected from version 8.0 of theMarshﬁeld genome
screening set, as described elsewhere (Liu et al. 2001).
The average heterozygosity of the markers used in this
study is 0.77, with an average density of 10 cM and a
few regions of denser coverage. Linkage map distances,
in Kosambi centimorgans, were obtained from the
Marshﬁeld Center for Medical Genetics (Broman et al.
1998).
PCR ampliﬁcation of microsatellite markers was per-
formed as described elsewhere (Aita et al. 1999; Liu et
al. 2001). PCR products were resolved using the PRISM
377XL data collection software, and base pair size was
called using GENESCAN, v. 2.1, and GENOTYPER, v.
1.1.1, software packages (Applied Biosystems). Com-
puter-generated genotypes were checked by an indepen-
dent researcher who was blind to each individual’s iden-
tity, pedigree, sex, and disease diagnosis. The genotypes
were then imported to the LABMAN database (Adams
1994). LABMAN was used to identify allele-binning er-
rors; LABMAN and PedCheck (O’Connell and Weeks
1998) were both used to identify Mendelization errors.
Biological relationships were reconﬁrmed using geno-
typic information with the program RelCheck (Broman
and Weber 1998).
Statistical and Genetic Analysis
Marker allele frequencies were estimated with
GCONVERT (Liu et al. 2002), using all genotyped in-
dividuals; this conservative estimation of frequencies di-
minishes the risk of type I error due to lack of parental
genotypes in a few families (Go¨ring and Terwilliger
2000a). Across the entire sample, 322 families include
both parents, 14 families are missing one parent, and 9
families are missing both parents. Multipoint ASP anal-
ysis of genotype data was performed using the Map-
maker/Sibs program (v. 2.1) that is part of the GENE-
HUNTER 2.1 software package (Kruglyak and Lander
1995; Kruglyak et al. 1996). Speciﬁcally, we used the
weighted “all pairs” option and set the increment func-
tion to scan at a distance of 1.0 cM throughout the
genetic map. ASP analysis calculates the probabilities of
sharing zero, one, or two alleles (z0, z1, or z2) identical
by descent (IBD) between sib pairs, since loci that are
involved in susceptibility to a trait will have probabilities
(z0, z1, and z2) that differ from the expected Mendelian
proportions (Risch 1990a, 1990b). Under the assump-
tion of dominance variation, we limited the sharing
probabilities to the “possible triangle,” as described else-
where (Faraway 1993; Holmans 1993), to ensure bio-
logical consistency; this is deﬁned by:
z  z  z p 1 ; z  .5 ; z  2# z .0 1 2 1 1 0
Two-point parametric analysis was performed on the
entire data set, using Fastlink (Lathrop et al. 1984; Cot-
tingham et al. 1993). We chose to use the pseudomarker
parameters for our two-point analysis (Go¨ring and Ter-
williger 2000b), which approximates a “model-free” af-
fected–relative-pair analysis but maintains the important
property of LOD-score analysis that pedigree correla-
tions between all relatives are considered jointly rather
than breaking the pedigree into a set of all possible rel-
ative pairs. Since the actual mode of inheritance for ASD
is unknown, both dominant and recessive models were
applied to our analyses.
Analysis on the X chromosome was performed using
Mapmaker/Sibs (v 2.0) (Kruglyak and Lander 1995).
This algorithm follows Cordell’s extension ofHolmans’s
method to analyze X-linked data by considering brother-
brother (bb), sister-brother (sb), and sister-sister (ss)
pairs separately (Cordell et al. 1995). To consider the
three groups independently, the maximization is re-
stricted to the following genetically valid values:
0  z  .5,0  z  .5,0  z  .5 ,1bb 1sb 1ss
where z1 represents IBD sharing of maternal alleles (Ny-
holt 2000). The sum of these threeMLS statistics, known
as “X-MLS,” is a mixture of x2 distributions with 1, 2,
and 3 df (Cordell et al. 1995; Nyholt 2000). Therefore,
to obtain a point-wise P value !.05, an X-MLS 11.18
is required, whereas evidence for suggestive and signif-
icant linkage is reached at X-MLS values of 3.06 and
4.62, respectively (Nyholt 2000). P values reported for
all chromosomes were determined according to the
guidelines presented by Nyholt (2000).
The broad and narrow data sets are not independent;
in fact, the narrow data set makes up 182% (285/345)
of the broad data set. No corrections were made to ac-
count for overlap between these analyses or for the over-
lap of the 110 families from our previous analysis and
the combined sample of 345 families in the complete
data set; instead, we present all information from the
analysis and allow readers to make their own interpre-
tations as to statistical signiﬁcance.
To clarify the interpretation of our linkage results, we
used simulated data sets to calculate empirical genome-
wide signiﬁcance values. Under the assumption of no
linkage, 100 replicates were simulated for both the nar-
row and broad data sets by use of the SIMULATE pro-
gram (Terwillger and Ott 1994). Each replicate was then
analyzed using GENEHUNTER 2.1. Genomewide sig-
niﬁcance was then determined on the basis of the number
of times an MLS was reached in the 100 replications.
Results
Results from the genomewide multipoint ASP analysis
are shown in ﬁgure 1. Linkage analysis produced MLS
peaks with a signiﬁcance level less than a pointwise
threshold of on 12 chromosomes (1, 2, 3, 4, 5,P ! .05
Figure 1 Multipoint MLS results from Mapmaker/Sibs ASP analysis, shown by chromosome. The X-axis depicts genetic distance in
Kosambi centimorgans from pter (zero coordinate) to qter; the Y-axis represents MLS for all autosomes and the X-MLS for the X chromosome.
Thin lines represent the narrow disease classiﬁcation; thick lines represent the broad disease classiﬁcation (see the “Families and Methods”
section). Black bars below the X-axis show regions with dense microsatellite marker coverage.
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7, 8, 10, 11, 17, 19, and X). The single largest peak
from the total set of 345 families is located on chro-
mosome 17q near marker D17S1800, with an MLS of
2.83 ( ), using the broad diagnostic classiﬁ-Pp .00029
cation (MLS of 0.85 with the narrow classiﬁcation). The
second highest MLS found in the entire genome was
2.54 ( ) on chromosome 5p near markerPp .00059
D5S2494, again using the broad classiﬁcation (MLS of
1.25 with the narrow classiﬁcation). Other regions of
interest include chromosome 11p between markers
D11S1392 and D11S1993, which produced an MLS of
2.24 ( ) with the broad classiﬁcation (MLS ofPp .0012
1.10 with the narrow classiﬁcation). The region on chro-
mosome 4q between markers D4S2361 and D4S2909
gave MLS values of 1.6 ( ) and 1.72 (Pp .0058 Pp
) with the narrow and broad classiﬁcations, re-.0043
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Table 2
Results of Analyses in 345 Families
CHROMOSOME






17 2.83 .000298 52 1.236c .0085 48
5 2.54 .000595 58 1.43c .0051 57
11 2.24 .0012 45 .496c .065 54
4 1.72 .0043 94 1.69c .0026 101
8 1.60 .0058 131 .812d .0266 135
NOTE.—Only the ﬁve chromosomal regions with MLS 1 1.4 (P !
) in the analysis of all 345 families are shown..01
a Two-tailed P values were calculated according to methods de-
scribed by Nyholt (2000).
b Position of the highest point/marker expressed as distance from
pter p 0
c Highest two-point LOD score obtained with a recessive model.
d Highest two-point LOD score obtained with a dominant model.
spectively. Also, the region on chromosome 8q near
marker D8S1832 gave an MLS of 1.6 ( ) withPp .0058
the narrow classiﬁcation and 1.5 ( ) with thePp .0074
broad classiﬁcation. All other chromosomal regions pro-
duced MLS values !1.4 ( ) or an X-MLS ! 1.9P 1 .01
( ) (Nyholt 2000). Multipoint ASP analysis wasP 1 .01
also preformed for the strictest deﬁnition of autism, as
opposed to our narrow category, which includes NQA;
however, the results were almost identical to those for
the narrow category (data not shown). Genomewide
two-point analysis (data not shown) identiﬁed peaks in
the same chromosomal regions as multipoint ASP anal-
ysis, although with consistently lower LOD scores, as
shown for several peaks in table 2.
On the basis of the linkage ﬁndings from the initial
set of 110 families (Liu et al. 2001), as well as several
independent studies, additional microsatellite markers
were added to chromosome 7q to generate dense cov-
erage (ﬁne map) across this important region. On the
basis of the linkage ﬁndings from an intermediate stage
of analysis (156 families; ), 10 additional chro-P ! .05
mosomal regions (3p, 4p, 4q, 5p, 8q, 10q, 15p, 16p,
17q, and 19q) were selected for dense-marker coverage.
In only 4 of the 11 regions observed, the addition of
ﬁne-map markers diminished evidence of linkage,
whereas in the remaining regions, evidence for linkage
was either maintained or increased, as illustrated by the
examples shown in table 3.
Figure 2 depicts several of the most interesting chro-
mosomal regions at three different stages of analysis
(stage 1 [110 families], stage 2 [156 families], and stage
3 [345 families]). Stage 2 represents a relatively small
addition of families; however, it is important, primarily
because the selection of dense-marker maps was based
on this analysis. None of the regions initially identiﬁed
in the stage 1 analysis showed substantial increase in
statistical signiﬁcance in the stage 3 analysis, although
suggestive evidence was maintained in support of chro-
mosomal regions 5p, 8q, and X. The signiﬁcances of
several regions implicated by the stage 2 analysis were
either maintained or increased in stage 3, including
regions on chromosomes 4, 11, and 17.
Our sample included a total of 30 pairs of MZ twins,
the 12 whose families were removed from analysis, as
well as 18 other pairs whose families were still usable
because of the presence of other affected siblings. All
60 of these individuals were completely genotyped so
that an estimate of the detectable genotyping error rate,
which came to 0.58%, could be calculated for this study.
Discussion
ASP analysis of 345 multiplex families, using both a
narrow and a broad diagnostic classiﬁcation (for autism
and ASD, respectively) revealed ﬁve chromosomal regions
with pointwise signiﬁcance values . In no singleP ! .01
region, however, did evidence for linkage reach the LOD
score threshold of 3.0 ( ) or the more conser-4Pp 10
vative threshold of 3.6 ( ) recommended5Pp 2.2# 10
for genomewide signiﬁcance with an inﬁnitely densemap
of markers (Lander and Kruglyak 1995). We conducted
simulation studies to compute a genomewide occurrence
expectation (OE), corresponding to our strongest MLS
of 2.83. When the 95% CI is included, this ﬁnding is
equivalent to an OE value of 0.09 (95% CI p 0.042–
0.165). An OE value of 0.09 reﬂects the fact that one
would expect to see an MLS of 2.83 once in every 11.1
(95% CI p 6–24) genome scans. These ﬁndings are of
particular interest in view of the fact that this carefully
controlled follow-up investigation represents the single
largest linkage study of autism and related spectrum dis-
orders reported to date. It is notable that the follow-up
analysis of 235 new families with autism were carefully
controlled to maintain consistent criteria and standards
for ascertainment scheme, diagnostic methods, genotyp-
ing methods, and genetic analysis, to an extent that
would be difﬁcult or impossible to match when com-
bining data from multiple independent studies.
The most signiﬁcant evidence for linkage was detected
on chromosome 17q, with an MLS of 2.83 (Pp
). We had previously detected nominal evidence.00029
for linkage to 17q from the stage 2 analysis of 156
families, which yielded an MLS of 1.95 ( )Pp .0024
(ﬁg. 2). Although this region was not identiﬁed in the
stage 1 scan, analysis of the next set of 189 families
(families added between stage 2 and stage 3) also pro-
duced nominal evidence for linkage to this same region
(MLS of 1.52) ( ). This same region of 17q wasPp .007
identiﬁed in an independent autism study, with an MLS
of 2.34 (IMGSAC 2001a).
The next strongest linkage signal mapped to chro-
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Table 3
Multipoint MLSs and Peak Positions in Three Separate Analyses
CHROMOSOME










4 94 .713 .054 92 1.72 .0043 94 1.72 .0043
5 0 1.44 .0085 0 .839 .0388 0 .869 .0359
5 59 2.01 .0021 60 1.89 .00285 59 2.54 .00059
8 130 1.71 .0044 132 .84 .0388 132 1.6 .0058
11 53 1.08 .021 46 2.24 .0012 … … …
17 49 .633 .0667 52 2.04 .00198 52 2.83 .00029
19 35 3.36 .000085 39 .686 .058 33 .778 .045
X 139 2.27 .0044 99 1.78 .003 … … …
NOTE.—Chromosomal regions with MLS 1 1.4 (P ! .01) in each analysis are underlined. For clar-
iﬁcation and comparison, we show the corrected results of the original 110 families for these regions
with the highest MLSs. Chromosomes 11 and X did not have any ﬁne map markers added, so the two
analyses of the 345 families are identical.
a Original 110 families reanalyzed with the updated pedigree and phenotype information fromAGRE.
b Total data set, without the additional high-density ﬁne-map markers; therefore, 335 microsatellite
markers covering the genome at 10-cM density.
c Total data set and ﬁne-map markers, with all 408 microsatellite markers.
d Position of the highest point expressed as distance from pter p 0.
e Two-tailed P values were calculated according to methods described by Nyholt (2000).
mosome 5p, with an MLS of 2.54 ( ) nearPp .00059
marker D5S2494. Analysis of the original 110 families
(stage 1), once updated for changes in pedigree structure
and individual diagnoses (see the “Families and Meth-
ods” section), produced an MLS of 2.0 ( ) atPp .0022
the same position near D5S2494 on 5p. Analysis of the
new set of 189 families alone did not provide much
evidence for linkage in this region (MLS of 0.82; Pp
), which helps explain why tripling the total number.04
of multiplex families and including the addition of
densely spaced DNA markers across this region pro-
duced only a slight increase in evidence for linkage to
ASD (ﬁg. 2). Although a previous study reported nom-
inal evidence for linkage to chromosome 5p (MLS of
.84) (Philippe et al. 1999), this region does not appear
to overlap with that reported in the present study. Three
other regions—on chromosomes 4q, 8q, and 11p—were
identiﬁed in the present analysis, withMLSs 11.4, which
appear to overlap with regions reported to have MLSs
11.0 in an independent genomewide scan with 75 fam-
ilies affected by autism (Barrett et al. 1999).
Figure 2 displays the comparative linkage patterns at
each of the three stages of analysis (110, 156, and 345
families). As shown, evidence in support of a number
of putative autism related regions is either maintained
or increased in the follow-up analyses; speciﬁcally, chro-
mosomes 4, 5, 7, 8, 11, 17, and X (most of which were
also identiﬁed from stage 2 analysis). In contrast, evi-
dence for linkage on chromosomes 16 and 19, which
was reported in the ﬁrst analysis of 110 families (Liu
et al. 2001), decreased in the follow-up analysis. Rean-
alysis of chromosome 16 after incorporating the minor
corrections in family relationship and diagnostic clas-
siﬁcation in the updated clinical database (see the “Fam-
ilies andMethods” section) eliminated evidence for link-
age to autism in this region from the original 110
families. In contrast, these same changes had the effect
of increasing statistical support for linkage to chro-
mosome 19. However, in spite of suggestive-to-sig-
niﬁcant linkage support from the stage 1 analysis
( ; ), we found no evidence ofMLSp 3.36 Pp .000085
linkage to the chromosome 19 region in the next 56
families or the subsequent 189 families (table 3). ASP
analysis of chromosome 3 at stage 2 (156 families) pro-
duced a relatively high LOD score ( ;MLSp 1.97
); however, evidence for linkage at this locusPp .002
was not supported by either the stage 1 or stage 3 anal-
yses (ﬁg. 2). Thus, we suspect the chromosome 3 data
represent false-positive results, especially because small
sample sizes are more susceptible to false-positive ﬁnd-
ings due to reduced power. These ﬁndings may also
reﬂect changes in the degree of genetic heterogeneity
among sample subgroups that could inﬂuence the out-
come of linkage analyses. Since we purposely adhered
to the same sampling scheme at each stage of our anal-
yses, we believe that biases arising from differences in
sample heterogeneity will be greater in small sample
subsets and that such effects will tend to be mitigated
in the entire sample of 345 families.
Four of the ﬁve most-suggestive regions identiﬁed in
Figure 2 Comparison of the three stages of ASP analysis for selected chromosomes. The X-axis depicts genetic distance in Kosambi
centimorgans from pter (zero coordinate) to qter; the Y-axis represents the MLS for all autosomes and the X-MLS for the X chromosome.
Thick red lines represent analysis of updated stage 1 (110 families) (see the “Families and Methods” section); hatched blue lines represent
analysis of stage 2 (156 families); and black lines represent analysis of stage 3 (345 families).
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this study are areas covered by high-density DNAmark-
ers. This led us to question whether the 10-cM scan
might be suboptimal to detect autism-related genetic
variation in the absence of the ﬁne-map markers. In-
stead, analysis with the original 335 markers, which
provide an average density of 10 cM over the entire
genome, identiﬁed most of the same regions, albeit with
lower levels of signiﬁcance in most cases (table 3).
Therefore, although the denser map is more informa-
tive, our data do not indicate that we are preferentially
detecting linkage in the densely mapped regions.
The linkage region implicated on chromosome 17q
is especially interesting, because it includes the serotonin
transporter (5-HTT) gene locus (SLC6A4). The marker
that gave the most signiﬁcant linkage score over the
entire genomewide scan, D17S1800, is ∼1 Mb distal of
5-HTT (UCSC Genome Bioinfomatics). The serotonin
transporter has previously been implicated as a candi-
date gene for autism on the basis of some, but certainly
not all, allelic association studies (Cook et al. 1997;
Klauck et al. 1997; Yirmija et al. 2001; Kim et al. 2002).
In addition, some reports show evidence of elevated
blood serotonin levels both in patients with autism and
in their unaffected ﬁrst-degree relatives (Cook and Lev-
enthal 1996), and other studies purport to show that
drugs that selectively target 5-HTT can ameliorate some
autism-related symptoms (Cook and Leventhal 1996).
More recently, a functional magnetic resonance imaging
study was coupled with a 5-HTT genotyping analysis,
to monitor changes in blood ﬂow to the amygdala in
response to the subjects’ processing of changes in facial
expression (Hariri et al. 2002). The study indicated that
amygdala activation is highly correlated with a pre-
sumptive functional polymorphism in the 5-HTT pro-
moter region. Although still quite speculative, these
ﬁndings are interesting in view of the diminished ca-
pacity to discern facial expressions among patients with
autism.
Linkage studies have been enormously successful for
mapping disease loci corresponding to rare disorders
with Mendelian inheritance patterns. However, when
applied to common, multigenic disorders, the very con-
nection that makes linkage studies possible (the high
correlation between genotype and phenotype) is often
lost (Weiss and Terwilliger 2000). The search for ge-
notype-phenotype correlations between microsatellite
DNA markers and highly reliable dichotomous disease
classiﬁcations for autism and ASD has produced nom-
inal-to-suggestive linkage evidence on varied chromo-
somes in many independent studies; however, only a
few of these regions overlap between studies or even in
follow-up studies performed by the same group. One
possible explanation for these ﬁndings is that inade-
quate sample sizes not only increase the likelihood of
false-positive ﬁndings but also lack the power to detect
linkage when individual gene-effect sizes are small and/
or when nonallelic heterogeneity is high. The present
follow-up study extends the sample size signiﬁcantly
beyond other autism studies reported to date. The ques-
tion remains whether this increase is signiﬁcant in re-
gard to the problems of false-positive and false-negative
ﬁndings described above. In regard to false-positive ﬁnd-
ings, it is striking that the majority of putative linkage
signals detected after stage 1 and stage 2 analyses were
maintained after the largest stage 3 analysis, yet it is
instructive that the single strongest ﬁnding from the up-
dated stage 1 analysis of 110 multiplex families appears
to have been a false-positive signal. Although a number
of putative disease loci detected in the early stages of
analysis were supported in the follow-up analysis, it is
interesting that evidence for linkage did not obviously
increase with the increase in sample size for any single
locus. Because further incremental increases in sample
size will challenge the capabilities of any single research
group, the need for large collaborative studies to pool
families and perform dense genotyping becomes clear.
However, we must also recognize the possibility that
even dramatic increases in sample size may fail to detect
linkage, or association, if the diagnosis of autism or
ASD does not signiﬁcantly increase the likelihood of
carrying any single genetic variant (Weiss and Terwil-
liger 2000). Thus, it will be important to identify and
characterize autism-related quantitative traits and/or
endophenotypes that are more directly correlated with
underlying genetic variation.
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